Search 

A University with profound academic rrsearch

investment fund

ZhongXi Capital focus on biomedical investment，fiancing，consulting and other capital market business.

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

总部位于浙江的上市公司

上海元亨祥股权投资基金集团有限公司（简称“元亨祥基金”），2012年8月落户于上海陆家嘴国际金融中心，2014年4月在中国证券投资基金业协会登记为“私募基金管理人”，下设元杏资产（其他类私募基金）、祥乾投资（股权类私募基金）、王道资产（证券类私募基金）。

作为风控型资产管理专家，元亨祥基金始终秉承“专业创造价值，安全方得安心”的品牌理念，顺应国家发展战略，携手世界500强名企太平洋建设、中国建筑、中冶天工等交易对手，积极引导社会资本投资“大基建、大康养、大文旅”领域，累计投资项目超过300个、累计投资规模超过300亿、累计撬动项目总规模超过3000亿，投资足迹遍布全国；同时，凭借投向明确、风控周密、期限合理、业绩领先、产品丰富五大优势，持续专注做好基建投资基金、证券投资基金、特色小镇基金、不动产基金、产业投资基金五大系列基金，为客户倾力打造专属投融资服务。

上海复星医药是China医药领军企业，在生物制药领域地位突出。

Shanghai复星医药（集团）股份有限公司（简称“复星医药”，股票代码：600196.SH，02196.HK）成立于1994 年，是China领先的医疗健康产业集团。复星医药的业务发展立足China、布局全球，以药品制造与研发为核心，覆盖医疗器械与医学诊断、医疗服务、医药分销与零售。

复星医药集团以创新研发为核心驱动因素，持续完善“仿创结合”的药品研发体系，打造了小分子创新药、高价值仿制药、生物药、细胞治疗等国际研发平台。

面向未来，复星医药集团在“4IN”（创新 Innovation、国际化 Internationalization、整合 Integration、智能化 Intelligentization）战略的指导下，秉承“持续创新·乐享健康”的品牌理念，致力于成为全球主流医疗健康市场的一流企业。